Physician profile

Thomas Drames

Critical Care Medicine (Internal Medicine) · Pennington, NJ

NPI 1003049610

$9,848.18

in general payments reported to CMS, 2019-2025

38 companies · $1,440 in 2025

The $1,440 reported for 2025 was more than what 83% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,540.15
Education$157.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $2,814.57 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Astrazeneca Pharmaceuticals LP $1,828.67 2019-2025 Fasenra, Tezspire, Breztri
Boehringer Ingelheim Pharmaceuticals, INC. $521.13 2019-2025 Ofev, Spiriva Respimat, Stiolto Respimat
Insmed, INC. $437.81 2019-2025 Arikayce
Mylan Specialty L.P. $423.07 2019-2024 Yupelri
Genentech USA, INC. $417.41 2019-2025 Xolair
Jazz Pharmaceuticals INC. $379.29 2019-2025
Amgen INC. $303.89 2022-2025 Tezspire
Harmony Biosciences LLC $266.39 2020-2025 Wakix
Genzyme Corporation $246.13 2020-2025
Regeneron Healthcare Solutions, INC. $237.76 2019-2025 Dupixent
Electromed, INC. $187.84 2022-2024 Smartvest
Inspire Medical Systems, INC. $179.36 2023-2025 Inspire
Verona Pharma, INC. $160.98 2025 Ohtuvayre
Axsome Therapeutics, INC. $156.19 2023-2025 Sunosi
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Actelion Pharmaceuticals US, INC. $156.14 2019-2023 Uptravi, Opsumit
Takeda Pharmaceuticals U.S.A., INC. $152.69 2020-2025 Aralast
Novartis Pharmaceuticals Corporation $133.51 2019-2023
Philips North America LLC $107.63 2019-2024 (Ak6) Vest Therapy
Vifor Pharma, INC. $93.31 2024-2025 Zemaira, Veltassa
Mallinckrodt Hospital Products INC. $92.70 2024-2025 Acthar
Avadel Cns Pharmaceuticals, LLC $80.39 2024 Lumryz
Grifols USA, LLC $68.68 2025 Prolastin-C Liquid
Advanced Respiratory, INC $55.63 2019-2021
United Therapeutics Corporation $53.16 2024 Tyvaso
Resmed Corp $32.32 2019
Kaleo, INC. $31.46 2021
Boston Scientific Corporation $27.73 2025 Watchman Flx
Teva Pharmaceuticals USA, INC. $27.30 2020-2021
Merck Sharp & Dohme LLC $25.62 2025
Masimo Corporation $23.37 2020
Paratek Pharmaceuticals, INC. $21.57 2024 Nuzyra
Viatris Specialty LLC $20.84 2025 Yupelri
Janssen Pharmaceuticals, INC $20.62 2019
Lilly USA, LLC $19.26 2025 Mounjaro, Zepbound
Idorsia Pharmaceuticals US INC $15.81 2024 Quviviq
Atricure, INC. $14.91 2019
Eisai INC. $13.04 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas Drames

$9,848.18

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $1,440 reported for 2025 was more than what 83% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).

https://glasscript.com/doctor/226594/thomas-drames

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.